News | March 28, 2026
Novartis acquires Excellergy to bolster allergy portfolio
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Subscribe To Our Newsletter & Stay Updated
